Oppenheimer Sees 50% Gain Coming To CLDX Near Term Catalyst,,
Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More
By Lee Jackson January 7, 2014
Celldex Therapeutics Inc. (NASDAQ: CLDX) focuses on developing therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines. Investors are interested in Celldex because of the unmet need therapies the company is developing. Celldex is working on drug indications that include therapies for glioblastoma, breast cancer, dense deposit disease and lymphoma. A recent secondary stock offering helped shore up the company coffers. The company is to update its CDX-1135 drug status, which could be a huge catalyst. The Oppenheimer price target is set at $40. The Thomson/First Call estimate is in line at $39.